MDT

95.27

+1.16%↑

VEEV

293.62

+2.3%↑

143.04

+3.86%↑

HQY

-2.12%↓

TLRY

1.57

-5.99%↓

MDT

95.27

+1.16%↑

VEEV

293.62

+2.3%↑

143.04

+3.86%↑

HQY

-2.12%↓

TLRY

1.57

-5.99%↓

MDT

95.27

+1.16%↑

VEEV

293.62

+2.3%↑

143.04

+3.86%↑

HQY

-2.12%↓

TLRY

1.57

-5.99%↓

MDT

95.27

+1.16%↑

VEEV

293.62

+2.3%↑

143.04

+3.86%↑

HQY

-2.12%↓

TLRY

1.57

-5.99%↓

MDT

95.27

+1.16%↑

VEEV

293.62

+2.3%↑

143.04

+3.86%↑

HQY

-2.12%↓

TLRY

1.57

-5.99%↓

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Atidarymo kaina

33.85 0.36

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.77

Max

34.62

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-15M -10M
Pardavimai	4.1M 98M
Pelno marža	-10.514
Darbuotojai	493
EBITDA	-11M -15M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+86.35% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2M 1.6B
Ankstesnė atidarymo kaina	33.49
Ankstesnė uždarymo kaina	33.85

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

27.895 / 30.16 Palaikymas ir pasipriešinimas

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-15 23:25; UTC

Pagrindinės rinkos jėgos

Salesforce Rises on New FY30 Financial Targets

2025-10-15 18:52; UTC

Uždarbis

Pagrindinės rinkos jėgos

Prologis Shares Gain on Raised Outlook, Data Center Growth

2025-10-15 18:30; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Software to Buy U.K.'s Tecvia Holding

2025-10-15 17:19; UTC

Įsigijimai, susijungimai, perėmimai

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

2025-10-15 17:11; UTC

Įsigijimai, susijungimai, perėmimai

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

2025-10-15 23:48; UTC

Rinkos pokalbiai

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

2025-10-15 23:38; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025-10-15 22:37; UTC

Rinkos pokalbiai

Economic Stars Are Aligning for RBA -- Market Talk

2025-10-15 21:44; UTC

Uždarbis

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

2025-10-15 20:50; UTC

Rinkos pokalbiai

Uždarbis

Financial Services Roundup: Market Talk

2025-10-15 20:44; UTC

Įsigijimai, susijungimai, perėmimai

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

2025-10-15 20:44; UTC

Įsigijimai, susijungimai, perėmimai

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

2025-10-15 20:43; UTC

Įsigijimai, susijungimai, perėmimai

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

2025-10-15 20:34; UTC

Uždarbis

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

2025-10-15 20:31; UTC

Įsigijimai, susijungimai, perėmimai

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

2025-10-15 20:17; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

2025-10-15 19:06; UTC

Uždarbis

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

2025-10-15 19:04; UTC

Rinkos pokalbiai

Oil Futures Post Back-to-Back Losses -- Market Talk

2025-10-15 18:46; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

2025-10-15 18:23; UTC

Uždarbis

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

2025-10-15 17:37; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

2025-10-15 17:34; UTC

Rinkos pokalbiai

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

2025-10-15 16:57; UTC

Uždarbis

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

2025-10-15 16:51; UTC

Įsigijimai, susijungimai, perėmimai

EssilorLuxottica Doesn't Disclose Financial Details

2025-10-15 16:50; UTC

Įsigijimai, susijungimai, perėmimai

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

2025-10-15 16:49; UTC

Įsigijimai, susijungimai, perėmimai

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

2025-10-15 16:48; UTC

Įsigijimai, susijungimai, perėmimai

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

2025-10-15 16:48; UTC

Įsigijimai, susijungimai, perėmimai

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

2025-10-15 16:47; UTC

Įsigijimai, susijungimai, perėmimai

EssilorLuxottica Buys Ikerian

2025-10-15 16:34; UTC

Rinkos pokalbiai

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

86.35% į viršų

12 mėnesių prognozė

Vidutinis 59.11 USD 86.35%

Aukščiausias 100 USD

Žemiausias 34 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

27.895 / 30.16Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.